MRUS - Merus Corp Company Projected Revenue

Official company branding of Merus (MRUS)

Merus N.V. relies on a virtual model, outsourcing production and testing to third-party contractors. The company's projected sales chart demonstrates a prolonged sideways corridor, where 0.06 expresses the latest metric level. Financial stability is based on the commercialization of unique patented drugs. The development strategy focuses on organic antibody trials and molecule licensing without pursuing mergers.

MRUS - Merus N.V. Company Expected Sales Volume over the range 07/04/2022 - 01/10/2026

Analytical breakdowns for Merus N.V.

- stock value and consensus price forecast:
Price Chart Merus N.V.|MRUS - Broker Consensus Forecast
- market capitalization statistics:
Market Value Merus NV|MRUS - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Value per Share Merus|MRUS - Total Stockholders' Equity|Market Value to Book Value Ratio merus.nl|MRUS - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Merus N.V.|MRUS - Long-Term Debt to Capital|Short-Term Debt to Equity Merus Corp|MRUS - Company Total Debt Obligations|Debt to Book Value Merus NV|MRUS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Merus|Quick Liquidity Indicator merus.nl
- earnings and market ratios statistics:
MRUS - Net Financial Result|Future Profit Merus N.V.|MRUS - Price to Earnings Ratio|Projected Price to Earnings Merus|MRUS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Merus NV|MRUS - Operating profit before deduction of amortization|Earnings per share for the last twelve months Merus|MRUS - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months merus.nl|MRUS - Earnings growth in current year|Net earnings per share growth forecast for next year Merus N.V.
- sales and revenue data:
MRUS - Company Gross Revenue|Projected Sales Volume Merus N.V.|MRUS - Market Cap to Revenue|Forward P/S Multiple Merus NV
Basic company analysis:Merus N.V. MRUS
Product sample of Merus Corp

Professional capital evaluates Merus N.V. (MRUS) through the lens of the future commercialization of bispecific antibodies, where the absence of current revenue is offset by an analysis of pipeline potential. This potential sales volume for Merus N.V. (MRUS) reflects the probable cash valuation of upcoming shipments, allowing the daily price action to filter out speculative noise and assess the purity of the momentum, despite the high risks associated with clinical trials.

Direct competitors

Company Projected Revenue Immutep Limited (IMMP)|anixa.com - Company Revenue Forecast|Company Projected Revenue Atossa Therapeutics, Inc. ATOS|CNTX - Company Future Sales Volume|Mersana - Projected Sales Volume|Company Expected Sales Volume BriaCell Corp|essapharma.com (EPIX) - Company Projected Revenue|qtimaging.com - Company Future Revenue